ArticleScientific reports2025
Mild hypothermia attenuates hepatic ischemia-reperfusion injury by regulating FoxO1/PPARα pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Regulatory Mechanisms Within Multicellular Signaling Networks in Liver Ischemia-Reperfusion Injury: A Systematic Review Focusing on Cell-Type-Specific Interactions.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Pooled it
- Potential regulation mechanism of lncRNA OIP5-AS1 influencing prognosis in acute myeloid leukemia patients via the miR-15a-5p/FOXO1 axis.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatic ischemia-reperfusion injury (IRI) is a common complication of hepatectomy and liver transplantation. As far as we know, mild hypothermia (MH) is an effective measure to alleviate liver IRI. However, the precise mechanisms have not been fully elucidated. This study investigated the regulatory role of FoxO1/PPARα-mediated energy metabolism in MH-alleviated IRI. Results showed a significant reduction in PPARα expression during liver IRI. Moreover, high PPARα level in post-IR liver specimens correlated with improved liver transplantation outcomes. MH increased blood glucose, elevated gluconeogenesis, and promoted fatty acid oxidation (FAO), indicating a high metabolic state, and also enhanced PPARα expression. Additionally, PPARα promoted FAO and gluconeogenesis, thereby enhancing MH's protective effects on hepatocytes. Mechanistically, MH promoted FoxO1-PPARα interaction, enhancing PCK1 and CPT1a transcription and boosting hepatic metabolism. Selective FoxO1 inhibition by AS1842856 worsened IRI and apoptosis by reducing gluconeogenesis and FAO, MH partially mitigated this damage and promoted energy metabolism. Additionally, through the FoxO1/PPARα pathway, MH inhibits BAX/Cytochrome C/Caspase-3 cascade-initiated apoptosis. Our findings suggest that MH alleviates liver IRI by activating FoxO1/PPARα-mediated energy metabolism and inhibiting the mitochondria-dependent apoptosis pathway, potentially providing a basis for broader MH application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.